Ken Romeril News Today

Scoop Community provides New Zealand Community news and views

The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit is a welcome way of drawing attention to the plight of NZ cancer patients desperate for treatments that are funded across the Tasman, but not here, says Myeloma NZ Chief Executive Dr Ken Romeril

Business Scoop provides news and views on Business and Markets from New Zealand

Scoop Community provides New Zealand Community news and views

03/02/2021 Watch: Ken Romeril on The AM Show. Credits: Video - The AM Show; Image - Getty A haematologist is calling for increased funding towards blood cancer treatments in New Zealand, arguing there is a lack of awareness regarding the diseases that kill an estimated 800 Kiwis each year. Ken Romeril, a haematologist with a specialist interest in myeloma, is the chief executive of Myeloma New Zealand, a non-profit organisation that focuses specifically on multiple myeloma and improving the liv...

Erratum PDF Download Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand Nicole Chien, Ken Romeril, Bart Baker, Hugh Goodman, Henry Chan, on behalf of the Myeloma Interest Group Published: 18 December 2020 (Vol 133 No 1527) In Table 1, the recommended dosage of Bortezomib in the VTD induction regimen was incorrectly reported as 1.3mg/m2. The correct recommended dosage is 1.5mg/m2. This error was resolved online and in the PD...